Experimental cancer therapy targets Tough-to-Treat myeloma

NCT ID NCT07620275

Recruiting now Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new treatment called KSVCBD for people with multiple myeloma that has come back or not responded to at least three prior treatments. KSVCBD is a type of CAR-T cell therapy given directly into the body to target two proteins (CD19 and BCMA) on myeloma cells. The study will enroll 9 participants to check safety and side effects first, with effectiveness as a secondary goal.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KSVCBD injection (a type of CAR-T cell therapy that targets CD19 and BCMA proteins on cancer cells)
What this could lead to: If it works, this could point toward a new treatment option for multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is a very early, small trial (only 9 people) focused on safety, not proof of effectiveness. Side effects like cytokine release syndrome or nerve problems are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Biotherapeutic Department of Chinese PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, 100853, China
Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University
NOT_YET_RECRUITING

Beijing, China
National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College
NOT_YET_RECRUITING

Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.